Cancer Cell
Volume 7, Issue 1, January 2005, Pages 25-37
Journal home page for Cancer Cell

Article
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics

https://doi.org/10.1016/j.ccr.2004.11.021Get rights and content
Under an Elsevier user license
open archive

Abstract

Telomere elongation by telomerase is repressed in cis by the telomeric protein TRF1. Tankyrase 1 poly(ADP-ribosyl)ates TRF1 and releases it from telomeres, allowing access of telomerase to telomeres. Here we demonstrate that tankyrase 1 inhibition in human cancer cells enhances telomere shortening by a telomerase inhibitor and hastens cell death. Conversely, either tankyrase 1 upregulation or telomere shortening, each of which decreased TRF1 loading on a chromosome end, attenuated the impact of telomerase inhibition. These results are consistent with the idea that telomeres having fewer TRF1s increase the efficiency of their elongation by telomerase. This study implies that both enzyme activity and accessibility to telomeres can be targets for telomerase inhibition.

Cited by (0)